v3.25.2
Operating Segments - Schedule of Operating Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule of Operating Segments [Line Items]      
External $ 1,306 $ 2,879 $ 1,347
Total 1,306 2,879 1,347
Segment loss (gain) 7,316 6,815 8,287
Company’s share of losses of company accounted for at equity, net   210 109
Equity losses from the investment in MitoCareX 429    
Finance expense (income), net (259) (1,164) (5,818)
Tax Income (expense) (14) 22 14
Loss 7,472 5,883 2,592
Segment Assets 10,171 11,182  
Segment Liabilities 1,420 1,595  
Drug Development [Member]      
Schedule of Operating Segments [Line Items]      
External
Total
Segment loss (gain) 4,873 5,359 8,405
Segment Assets 8,407 7,069  
Segment Liabilities 1,194 1,441  
Online Sales [Member]      
Schedule of Operating Segments [Line Items]      
External 1,306 2,879 1,347
Total 1,306 2,879 1,347
Segment loss (gain) 2,443 1,456 $ (118)
Segment Assets 1,764 4,113  
Segment Liabilities $ 226 $ 154